About Cordlife
About Cordlife


  • 2001

    CordLife Pte Ltd established and licensed by Ministry of Health (MOH) Singapore

  • 2002

    First cord blood released for sibling-use.

    Laboratory at Camden Medical Centre opened for public viewing.

  • 2005

    Received accreditation from American Association of Blood Banks (AABB)

    AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility.

    Offered Medicord, a stem cell transplant insurance programme.

    Entered Hong Kong and People's Republic of China (PRC) markets.

  • 2007

    Expanded to new Science Park II facility.

    Cordlife Hong Kong achieved ISO:9001.

  • 2008

    Re-accredited by American Association of Blood Banks (AABB).

    Launch of automated processing system to maximise recovery of cells for transplant use.

  • 2009

    Re-accredited by American Association of Blood Banks (AABB).

    First-ever release of autologous cord blood for Cerebral Palsy

    Launched Cordlife Quality Guarantee, a warranty to protect Cordlife clients.

    Launched Cordlife Circle, a members-only benefit programme.

    Launched Preferential Plan upgrades for clients.

  • 2010

    First-ever release of autologous cord blood for Neuroblastoma.

    Released autologous cord blood for Cerebral Palsy.

    Celebrated enrolment of our 25,000th client.

    Celebrated 10 years of quality cord blood banking.

  • 2011

    CordLife Pte Ltd renamed to "Cordlife Group Limited".

    Launched Cordlife Care360° Safeguard programme.

    Re-accredited by American Association of Blood Banks (AABB).

    Launched provision of umbilical cord tissue banking services in Hong Kong.

    Hong Kong facility accredited by American Association of Blood Banks (AABB)

  • 2012

    Successfully listed on Singapore Exchange Main Board on 29 March 2012.

    More than 40,000 clients stored their precious stem cells with Cordlife.

  • 2013

    Cordlife Group Limited moved to its fully owned, 23,000sqft office and laboratory facility in A'Posh Bizhub, Yishun. The facility is capable of storing up to 650,000 cord blood units.

    First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*.

    Re-accredited by American Association of Blood Banks (AABB).

    Launched provision of umbilical cord lining banking services in Singapore with patented technology, CellOptima that is exclusively available at Cordlife capable of isolating EpSCs and MSCs, two types of stem cells present in the umbilical cord.

    Awarded 'Most Transparent Company Award' by SIAS Investors Choice

  • 2014

    Processed and stored over 45,000 cord blood units as of 21 March 2014.

    Collaborated with Make-A-Wish Foundation® (Singapore) Ltd granting the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy.

    Enhanced Cordlife Pledge:360° assures quality processing and storage standards.

  • 2015

    Received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices.

    Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy).

    Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund with a sponsorship of $150K to give young children from low-income families a chance in pre-school education.

    Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments.

    Received the 16th SIAS Investors Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category

    Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015.

    Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.

  • 2016

    Cordlife India received accreditation from College of American Pathologists (CAP)

    Awarded by Frost & Sullivan as the Stem Cell banking Company of the Year in Asia.

  • 2017

    Cordlife India clinches the Gold as the Best Social Media Healthcare Brand in an online voting survey conducted by Social Samosa, a renowned Online Media Publication.

    Released Cord Blood Unit for sibling related treatment of Thalassemia major in West Bengal.

  • 2018

    Completed a Decade of Operations in India.

  • 2019

    Introduced AXP II, an automated and functionally closed and sterile Cord Blood Processing technology, approved by FDA and cGMP & cGTP compliant.

    Launched Cordlife Diagnostics in association with Sandor Speciality Diagnostics Pvt. Ltd.

    Launched Cord Blood Banking in Bangladesh and Africa.

*Conditions apply.